GANNON STEVEN — SEC Form 4 filings
SEC reporting owner CIK 1643085. 8 Form 4 filings on record with FilingPulse; latest filed 2026-08-13.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2024-03-08 to 2026-08-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 3 filings — 23,003 shares, $1,242,256 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: sale of 10,000 shares @ $64.06 ($640,550) in Xenon Pharmaceuticals Inc., filed 2026-08-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | Director | 7 | — | 6 legs · 23,003 sh · $1,242,256 | 12 |
| Fusion Pharmaceuticals Inc. (FUSN) | Director | 1 | — | — | 6 |
Form 4 filings — GANNON STEVEN
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-13 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Sale (S): 10,000 @ $64.06 | EDGAR |
| 2026-06-03 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Option exercise (M): 2,645 · Tax withholding (F): 1,416 @ $53.41 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Option exercise (M): 3,500 @ $7.38 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Sale (S): 3 @ $30.48 · Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Option exercise (M): 5,144 @ $12.57 · Option exercise (M): 5,144 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Grant/award (A): 15,542 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Fusion Pharmaceuticals Inc. (FUSN) | Disposition to issuer (D): 56,400 · Disposition to issuer (D): 141,011 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-03-08 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Sale (S): 1,000 @ $46.45 · Sale (S): 5,000 @ $46.25 · Sale (S): 5,000 @ $46.30 · Sale (S): 2,000 @ $46.20 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1643085 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →